PetVivo (NASDAQ:PETV) Shares Up 1.1%

PetVivo Holdings, Inc. (NASDAQ:PETV)’s stock price shot up 1.1% during trading on Wednesday . The stock traded as high as $0.46 and last traded at $0.46. 23,653 shares were traded during mid-day trading, a decline of 44% from the average session volume of 42,518 shares. The stock had previously closed at $0.45.

PetVivo Trading Up 1.1 %

The company’s 50 day simple moving average is $0.68 and its two-hundred day simple moving average is $0.94. The stock has a market cap of $9.04 million, a price-to-earnings ratio of -0.53 and a beta of 2.24. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.62 and a current ratio of 0.90.

Insider Buying and Selling

In related news, CEO John Lai purchased 150,000 shares of PetVivo stock in a transaction on Monday, April 15th. The stock was purchased at an average cost of $0.60 per share, with a total value of $90,000.00. Following the acquisition, the chief executive officer now directly owns 1,288,592 shares in the company, valued at $773,155.20. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 20.10% of the stock is owned by insiders.

Hedge Funds Weigh In On PetVivo

An institutional investor recently bought a new position in PetVivo stock. Warberg Asset Management LLC acquired a new position in shares of PetVivo Holdings, Inc. (NASDAQ:PETV) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 27,693 shares of the company’s stock, valued at approximately $29,000. Warberg Asset Management LLC owned 0.19% of PetVivo as of its most recent filing with the Securities and Exchange Commission. 24.55% of the stock is currently owned by institutional investors and hedge funds.

PetVivo Company Profile

PetVivo Holdings, Inc, a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.